| Clobetasol and halcinonide act as smoothened agonists to promote myelin gene expression and RxRă receptor activation G Porcu, E Serone, V De Nardis, D Di Giandomenico, G Lucisano, ... PloS one 10 (12), e0144550, 2015 | 36 | 2015 |
| Polymorphisms of the IgH enhancer HS1. 2 and risk of systemic lupus erythematosus D Frezza, B Tolusso, V Giambra, E Gremese, M Marchini, M Nowik, ... Annals of the rheumatic diseases 71 (8), 1309-1315, 2012 | 31 | 2012 |
| Interim analysis of the myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high … JO Mascarenhas, JT Prchal, A Rambaldi, RA Mesa, D Berenzon, ... Blood 128 (22), 479, 2016 | 28 | 2016 |
| Safety and efficacy of combined ruxolitinib and decitabine in patients with blast-phase MPN and Post-MPN AML: results of a phase I study (myeloproliferative disorders research … RK Rampal, JO Mascarenhas, HE Kosiorek, D Berenzon, E Hexner, ... Blood 128 (22), 1124, 2016 | 20 | 2016 |
| Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort M Mirani, G Favacchio, E Serone, G Lucisano, MC Rossi, CC Berra Pharmacological Research 137, 270-279, 2018 | 19 | 2018 |
| The change in Ig regulation from children to adults disconnects the correlation with the 3˘RR hs1. 2 polymorphism E Serone, C Daleno, N Principi, L Porretti, V Iacoacci, C Gargioli, ... BMC immunology 15, 1-5, 2014 | 7 | 2014 |
| Association between Psoriasis and haplotypes of the IgH 3'Regulatory Region 1 P D'Addabbo, E Serone, M Esposito, G Vaccari, C Gargioli, D Frezza, ... Gene 669, 47-51, 2018 | 6 | 2018 |
| Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: interim … RA Mesa, R Hoffman, HE Kosiorek, JT Prchal, CN Harrison, MF McMullin, ... Blood 128 (22), 4271, 2016 | 6 | 2016 |
| The involvement of IgH enhancer HS1. 2 in the pathogenesis of Crohn's disease: how the immune system can influence a multifactorial disease. R Cianci, S Lolli, D Pagliari, G Gambassi, S Frosali, R Marmo, G Melioli, ... European Review for Medical & Pharmacological Sciences 20 (17), 2016 | 6 | 2016 |
| Association between the response to B cell depletion therapy and the allele* 2 of the HS1, 2A enhancer in seropositive rheumatoid arthritis patients S Canestri, MC Totaro, E Serone, B Tolusso, D Frezza, E Gremese, ... Reumatismo 64 (6), 368-373, 2012 | 5 | 2012 |
| Association between IgH enhancer hs1. 2 and type 1 diabetes R Cianci, P D˘Addabbo, G Gambassi, S Lolli, E Serone, A Rizzi, D Pitocco, ... Acta diabetologica 55, 443-448, 2018 | 4 | 2018 |
| Exploring the potential of JAK1/2 inhibitor ruxolitinib with reduced intensity hematopoietic cell transplantation (HCT) for myelofibrosis: stage I results of a prospective … V Gupta, HE Kosiorek, RB Klisovic, JP Galvin, D Berenzon, A Yacoub, ... Blood 128 (22), 1126, 2016 | 3 | 2016 |
| The functional VNTR of IGH enhancer HS1.2 associates with human longevity and interacts with TNFA promoter diplotype in a population of Central Italy V Napolioni, E Serone, V Iacoacci, FM Carpi, V Giambra, D Frezza Gene, 2014 | 3 | 2014 |
| HS1, 2 Ig enhancer alleles association to AIDS progression in a pediatric cohort infected with a monophyletic HIV-strain C Montesano, V Giambra, D Frezza, P Palma, E Serone, GC Gattinara, ... BioMed Research International 2014, 2014 | 3 | 2014 |
| Concerted variation of the 3′ regulatory region of Ig heavy chain and Gm haplotypes across human continental populations D Frezza, C Martinez‐Labarga, V Giambra, E Serone, G Scano, ... American Journal of Physical Anthropology 171 (4), 671-682, 2020 | 2 | 2020 |
| Balkan endemic nephropathy risk associates to the hs1. 2 Ig enhancer polymorphism D Frezza, E Serone, S Lolli, R Cianci, P D'Addabbo, C Mattioli, V Giambra, ... European Journal of Inflammation 10 (3), 393-403, 2012 | 2 | 2012 |
| New insight of human-IgH 3′ regulatory regions in immunoglobulins switch R Cianci, G Mancino, E Galli, E Serone, R Massoud, P D'Addabbo, ... Gene 862, 147254, 2023 | | 2023 |
| ASSSOCIATION OF THE 22 GENOTYPE OF ENHANCER HS1, 2A OF THE IG HEAVY 3'REGULATORY REGION WITH NON RESPONSE TO DMARDS AND RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS PATIENTS B Tolusso, E Gremese, AL Fedele, E Serone, D Frezza, MR Gigante, ... ANNALS OF THE RHEUMATIC DISEASES 72, 213-213, 2013 | | 2013 |
| AB0023 Gene-gene interaction and early rheumatoid arthritis: effects on the response to therapy MC Totaro, B Tolusso, FM Carpi, AL Fedele, V Napolioni, S Canestri, ... Annals of the Rheumatic Diseases 71 (Suppl 3), 638-638, 2013 | | 2013 |
| THU0148 Asssociation of the 22 Genotype of Enhancer HS1, 2A of the IG Heavy 3′ Regulatory Region with Non Response to Dmards and Response to Rituximab in Rheumatoid Arthritis … B Tolusso, E Gremese, AL Fedele, E Serone, D Frezza, MR Gigante, ... Annals of the Rheumatic Diseases 72 (Suppl 3), A213-A213, 2013 | | 2013 |
Pietro D'AddabboTechnician, University of BaryVerified email at uniba.it
